Proteome-based epitopic peptide scanning along PSA.

The specific definition of the immunogenic peptide repertoire from tumor-associated-antigens (TAAs) is of crucial importance for designing effective immunotherapeutical treatments. Multiple mechanisms, at different levels and in complementary manners, contribute to the generation of immunogenic peptides. Using as an experimental model the prostate specific antigen (PSA) and a murine monoclonal antibody (MAb) raised against human PSA, the role of PSA peptide 1) similarity to the murine proteome, 2) affinity to H2-Ad/Ed molecules, and 3) proteasomal cleavage pattern were investigated. We report that the core of the interaction between the anti-PSA MAb ER-PR8 and the prostatic antigen is located in the pentapeptide motif PSA(27-31)GGWEC. The pentapeptide motif is characterized by having no sequence similarity to the murine proteome and a low number of potential proteolytic sites.

[1]  Bjoern Peters,et al.  Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications , 2005, Immunogenetics.

[2]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[3]  K. Hadeler,et al.  PAProC: a prediction algorithm for proteasomal cleavages available on the WWW , 2001, Immunogenetics.

[4]  H. Rittenhouse,et al.  Polyclonal and monoclonal antibodies to prostate-specific antigen can cross-react with human kallikrein 2 and human kallikrein 1. , 1999, Urology.

[5]  A. Waheed,et al.  The biosynthesis of prostate-specific antigen in non prostatic cell lines. , 2001, Clinical biochemistry.

[6]  M. Varma,et al.  Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: Implications for diagnostic prostatic pathology. , 2002, American journal of clinical pathology.

[7]  P. Dönnes,et al.  Integrated modeling of the major events in the MHC class I antigen processing pathway , 2005, Protein science : a publication of the Protein Society.

[8]  P. Schneider,et al.  Hepatitis B surface antigen presentation and HLA‐DRB1*– lessons from twins and peptide binding studies , 2005, Clinical and experimental immunology.

[9]  A. Sigalov.  Multichain immune recognition receptor signaling from spatiotemporal organization to human disease. Preface. , 2008, Advances in experimental medicine and biology.

[10]  F. Marincola,et al.  Sequence uniqueness and sequence variability as modulating factors of human anti-HCV humoral immune response , 2008, Cancer Immunology, Immunotherapy.

[11]  Georgia Sotiropoulou,et al.  Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer. , 2008, Clinical biochemistry.

[12]  Jim Miller,et al.  Endosomal proteases and antigen processing. , 1997, Trends in biochemical sciences.

[13]  B. Martoglio,et al.  Intramembrane Proteolysis of Signal Peptides: An Essential Step in the Generation of HLA-E Epitopes1 , 2001, The Journal of Immunology.

[14]  P. Srivastava.  Immunotherapy for human cancer using heat shock protein-peptide complexes , 2005, Current oncology reports.

[15]  U. Stenman,et al.  Epitope mapping of antibodies against prostate-specific antigen with use of peptide libraries. , 2002, Clinical chemistry.

[16]  J. McCluskey,et al.  T Cell Determinants Incorporating β-Amino Acid Residues Are Protease Resistant and Remain Immunogenic In Vivo1 , 2005, The Journal of Immunology.

[17]  Yoram Louzoun,et al.  T-cell epitope repertoire as predicted from human and viral genomes. , 2006, Molecular immunology.

[18]  K Eichmann,et al.  Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. , 1995, Immunity.

[19]  G. Sotiropoulou,et al.  Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. , 2007, Biochimica et biophysica acta.

[20]  Alberta Lucchese,et al.  Monoclonal and polyclonal humoral immune response to EC HER‐2/NEU peptides with low similarity to the host's proteome , 2002, International journal of cancer.

[21]  E. Appella,et al.  The sites of antigen-T cell and antigen-MHC interactions overlap. , 1985, Journal of immunology.

[22]  R. Vessella,et al.  Prostate-specific antigen: characterization of epitopes by synthetic peptide mapping and inhibition studies. , 1997, Clinical chemistry.

[23]  D. Margulies,et al.  Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR. , 1995, Journal of immunology.

[24]  Darja Kanduc,et al.  Immunogenicity in peptide-immunotherapy: from self/nonself to similar/dissimilar sequences. , 2008, Advances in experimental medicine and biology.

[25]  S. Stevanović,et al.  Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells. , 2005, Blood.

[26]  Matthew W. Anderson,et al.  Cooperativity during the formation of peptide/MHC class II complexes. , 2005, Biochemistry.

[27]  A. Sette,et al.  Immunogenicity of self antigens is unrelated to MHC-binding affinity: T-cell determinant structure of Golli-MBP in the BALB/c mouse. , 2000, Journal of autoimmunity.

[28]  W. J. Allard,et al.  Analysis of Monoclonal Antibodies to Prostate-Specific Antigen: Reactivity with Native and Recombinant Prostate-Specific Antigen , 1999, Tumor Biology.

[29]  S. Braun,et al.  Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells , 2004, Histochemistry.

[30]  Alberta Lucchese,et al.  Individuation of monoclonal anti-HPV16 E7 antibody linear peptide epitope by computational biology , 2001, Peptides.

[31]  B. Halassy,et al.  Immunogenicity of peptides of measles virus origin and influence of adjuvants. , 2006, Vaccine.

[32]  F. Marincola,et al.  Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. , 2003, Biochimica et biophysica acta.

[33]  Alberta Lucchese,et al.  Computer‐assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences , 2000, Immunology and cell biology.

[34]  R. Dummer,et al.  Non‐self‐discrimination as a driving concept in the identification of an immunodominant HMW‐MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients , 2004, International journal of cancer.

[35]  D. Bonamonte,et al.  Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: a case report , 2006, Journal of Translational Medicine.

[36]  Reinhard Dummer,et al.  Identification of monoclonal anti-HMW-MAA antibody linear peptide epitope by proteomic database mining. , 2004, The Journal of investigative dermatology.

[37]  Jian Zhang,et al.  The Protein Information Resource: an integrated public resource of functional annotation of proteins , 2002, Nucleic Acids Res..

[38]  A. Miller,et al.  Dominance and crypticity of T cell antigenic determinants. , 1993, Annual review of immunology.